ArticleFrontiers in oncology2025
Determining optimal clinical target volume margins based on microscopic tumor extension in patients with non-small-cell lung cancer undergoing chemotherapy or chemotherapy combined with immunotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is currently no unified understanding of the clinical target volume (CTV) margins for radiotherapy in non-small cell lung cancer (NSCLC), after chemotherapy or chemotherapy combined with immunotherapy. This study aimed to explore margins around the gross tumor volume (GTV) to infer the CTV in NSCLC, after chemotherapy or chemotherapy combined with immunotherapy, using microscopic tumor extension (ME). Methods: We retrospectively analyzed 185 patients with stage II and III NSCLC who underwent surgery without neoadjuvant therapy or with neoadjuvant chemotherapy or chemotherapy combined with immunotherapy. We assessed the correlation between the radiological (last preoperative computed tomography image) and pathological (postoperative gross specimens) tumor size, measured the distance of ME under a digital microscope, and determined the correlation between clinicopathological characteristics and ME. Results: For the same tumor sample, a significant correlation was observed between the radiological and macroscopic sizes (r=0.836). With a 5% error risk, we applied a margin of 6.80 mm and 6.00 mm to the adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of direct surgery, respectively; a margin of 5.20 mm and 4.20 mm, to the ADC and SCC receiving chemotherapy, respectively; and a margin of 4.60 mm and 1.20 mm to the ADC and SCC receiving chemotherapy combined with immunotherapy, respectively. The ME value of a tumor correlated with the pathological type, tumor stage, and preoperative treatment methods. Conclusions: Different CTV margins should be adopted for patients with NSCLC who are receiving different treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.